NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer

D Thomson; H Yang; H Baines; E Miles; S Bolton; C West; N Slevin

NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer

D Thomson, H Yang, H Baines, E Miles, S Bolton, C West, N Slevin

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	344-347
Number of pages	3
Journal	Clinical Oncology
Volume	26
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Identifying molecular markers for improving the outcomes of radiotherapy and leading to spin out company Mantra Diagnostics
West, C. (Corresponding participant), Choudhury, A. (Participant), Hoskin, P. (Participant) & Smith, T. (Participant)
Impact: Health and wellbeing, Economic

Cite this

@article{ece74456b70e4ed0b3ee42c092985fba,

title = "NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer",

author = "D Thomson and H Yang and H Baines and E Miles and S Bolton and C West and N Slevin",

year = "2014",

language = "English",

volume = "26",

pages = "344--347",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer

AU - Thomson, D

AU - Yang, H

AU - Baines, H

AU - Miles, E

AU - Bolton, S

AU - West, C

AU - Slevin, N

PY - 2014

Y1 - 2014

M3 - Article

SN - 0936-6555

VL - 26

SP - 344

EP - 347

JO - Clinical Oncology

JF - Clinical Oncology

ER -

NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer

UN SDGs

Impacts

Identifying molecular markers for improving the outcomes of radiotherapy and leading to spin out company Mantra Diagnostics

Cite this